1. Home
  2. ENTO vs CNEY Comparison

ENTO vs CNEY Comparison

Compare ENTO & CNEY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTO
  • CNEY
  • Stock Information
  • Founded
  • ENTO 2014
  • CNEY 2018
  • Country
  • ENTO United States
  • CNEY China
  • Employees
  • ENTO N/A
  • CNEY N/A
  • Industry
  • ENTO Biotechnology: Pharmaceutical Preparations
  • CNEY Major Chemicals
  • Sector
  • ENTO Health Care
  • CNEY Industrials
  • Exchange
  • ENTO Nasdaq
  • CNEY Nasdaq
  • Market Cap
  • ENTO 1.2M
  • CNEY 1.0M
  • IPO Year
  • ENTO 2016
  • CNEY 2021
  • Fundamental
  • Price
  • ENTO $0.62
  • CNEY $0.63
  • Analyst Decision
  • ENTO
  • CNEY
  • Analyst Count
  • ENTO 0
  • CNEY 0
  • Target Price
  • ENTO N/A
  • CNEY N/A
  • AVG Volume (30 Days)
  • ENTO 924.5K
  • CNEY 20.1M
  • Earning Date
  • ENTO 10-21-2024
  • CNEY 01-01-0001
  • Dividend Yield
  • ENTO N/A
  • CNEY N/A
  • EPS Growth
  • ENTO N/A
  • CNEY N/A
  • EPS
  • ENTO N/A
  • CNEY N/A
  • Revenue
  • ENTO N/A
  • CNEY $66,509,375.00
  • Revenue This Year
  • ENTO N/A
  • CNEY N/A
  • Revenue Next Year
  • ENTO N/A
  • CNEY N/A
  • P/E Ratio
  • ENTO N/A
  • CNEY N/A
  • Revenue Growth
  • ENTO N/A
  • CNEY 35.10
  • 52 Week Low
  • ENTO $0.19
  • CNEY $0.26
  • 52 Week High
  • ENTO $14.51
  • CNEY $3.60
  • Technical
  • Relative Strength Index (RSI)
  • ENTO 59.35
  • CNEY 50.94
  • Support Level
  • ENTO $0.38
  • CNEY $0.60
  • Resistance Level
  • ENTO $0.87
  • CNEY $0.68
  • Average True Range (ATR)
  • ENTO 0.14
  • CNEY 0.07
  • MACD
  • ENTO 0.03
  • CNEY -0.02
  • Stochastic Oscillator
  • ENTO 52.57
  • CNEY 39.41

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

About CNEY CN Energy Group Inc.

CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.

Share on Social Networks: